Skip to main content

NNIT A/S: 11/2020 Financial report for the first nine months of 2020

Written by Customer Service on . Posted in Public Companies.

NNIT A/S: 11/2020 Financial report for the first nine months of 2020Revenue decrease of 7.8% to DKK 2.081m and an operating profit margin before special items of 5.3% in the first nine months of 2020Performance highlights for the third quarter of 2020:Group revenue decreased by 14% to DKK 658m in Q3 2020 compared to Q3 2019. Positivly, revenue from life sciences international continued the growth path with revenue increasing by 29% to 122m while revenue from life sciences Denmark increased by 3.2% to 59m. In Q3 2020 other life science generated more revenue than the Novo Nordisk groupRevenue from the Novo Nordisk Group continued the expected decline (-27%). Consequently, the share of NNIT’s revenue from clients outside the Novo Nordisk Group increased to 75% in Q3 2020 from 71% in Q3 2019The COVID-19 situation continued to impact performance in Q3 2020 due to the ongoing uncertainty leading to delays of tenders and projectsOperating profit margin before special items at 3.8% in Q3 2020 compared to 9.0% in Q3 2019Net profit at DKK 9m in Q3 2020 compared to DKK 50m in Q3 2019 due to the lower operating profit and negative impact from net financialsFree cashflow at a conversion rate of 78%Order backlog for 2020 at the beginning of Q4 2020 at DKK 2,691m, a decrease of 7.9% compared to the same time last year impacted by a large decline of 27% from the Novo Nordisk GroupOutlook for 2020:COVID-19 continues to impact our business negatively by delaying project work and tenders and we now expect that our performance for 2020 will be at the bottom of previously guided intervals. Hence, our guidance for 2020 is specified as follows provided no further deteriation in relation to the COVID-19 situation:Revenue growth of around – 8% in constant currenciesOperating profit margin before special items of around 6% in constant currenciesLevel of investment (CAPEX) is 5-7% of total revenue (unchanged)Per Kogut, CEO at NNIT comments: “NNIT’s Q3 was driven by double digit profitable growth in the international life sciences segment. The Novo Nordisk Group impacted the growth negatively as expected. In addition, the private & public business contracted in Q3. The Q3 performance evidences the importance for NNIT of having different main business segments to execute on during challenging times.”Conference call details
NNIT will host a teleconference October 29, 2020 at 10:30 CET about the financial report for the first nine months of 2020. Please visit the NNIT webpage at www.nnit.com to access the teleconference, which can be found under ‘Investors – Events & presentations. Presentation material will be available on the website approximately one hour prior to the start of the presentation.Conference call details
https://nnit.eventcdn.net/2020q3/Participant telephone numbers:
Denmark:                                     +45 45 7815 0109
United Kingdom:                       +44 333 300 9032
Sweden:                                        +46 850 558 356
United States:                            +1 646 722 4904Financial Calendar 2021
January 26, 2021                       Deadline for NNIT shareholders to submit resolutions to be considered by the Annual General Meeting
January 29, 2021                       Annual report 2020
March 10, 2021                          Annual General Meeting
May 7, 2021                                 Interim report for the first three months of 2021
August 12, 2021                        Interim report for the first six months of 2021
November 3, 2021                   Interim report for the first nine months of 2021Forward-looking statements
This announcement contains forward-looking statements. Words such as ‘believe’, ‘expect’, ‘may’, ‘will’, ‘plan’, ‘strategy’, ‘prospect’, ‘foresee’, ‘estimate’, ‘project’, ‘anticipate’, ‘can’, ‘intend’, ‘outlook’, ‘guidance’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future operating or financial performance identify forward-looking statements. Statements regarding the future are subject to risks and uncertainties that may result in considerable deviations from the outlook set forth. Furthermore, some of these expectations are based on assumptions regarding future events which may prove incorrect.
Please also refer to the overview of risk factors in the ‘risk management’ section on page 29-31 in the Annual Report 2019.Contacts for further information
Investor relations:                              Media relations:                
Jens Binger                                          Tina Joanne Hindsbo
Head of Investor Relations          NNIT Communications                 
Tel: +45 3079 9222                          Tel: +45 3077 9578                         
jblb@nnit.com                                  tnjh@nnit.com                                                                  About NNIT
NNIT A/S is one of Denmark’s leading IT service providers and consultancies. NNIT A/S offers a wide range of IT services and solutions to its customers, primarily in the life sciences sector in Denmark and internationally and to customers in the public, enterprise and finance sectors in Denmark. As of June 30, 2020, NNIT A/S had 3,078 employees. NNIT has approximately 400 clients of which around 150 are located outside Denmark. Some 25% are international life sciences clients. For more information please visit www.nnit.com.Attachment11 20201029 Company announcement Q3 2020_EN_v1

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.